Research Programs

Viral connections to cancer

Using capture-seq approaches pioneered in work with the USDA on foreign and emerging animal diseases, we are collaborating with physicians in the US and abroad to screen clinical samples and tumor biopsies for the genetic signatures of viruses.

We are also studying genetic mutations and gene expression patterns in both host cells and viruses in order to better understand the contributions of viruses to cancer and to identify molecular pathways that might be exploited in the development of antiviral or anticancer therapeutics.

The McIntosh Lab has a variety of ongoing and recently completed research programs supported by the financial contributions of the University of Florida, Department of Pediatrics; the Children’s Miracle Network; USDA APHIS; DHS S&T; and NIH NCI and NIH NIDCR.


Sponsored Research Programs

Active Projects

Regulation of latent and lytic phases of EBV

PIs: Sumita Bhaduri-McIntosh, M.D., and Michael McIntosh, Ph.D.

7/1/2024 – 6/30/2025

International Biobank for Virus-associated Lymphomas and Cancers

PI: Michael McIntosh, Ph.D.
Sponsor:
Children’s Miracle Network (2909CMCNT)

9/01/2023 – 08/31/2028

Exposing synthetic lethal vulnerabilities in EBV-positive AIDS-NHL through novel replication dependency factors

PI: Sumita Bhaduri-McIntosh, M.D.
Co-I: Michael McIntosh, Ph.D.
Sponsor: NATL INST OF HLTH NIDCR
NIH, NIDCR R01 DE032623

09/2022 – 08/2027

Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV

PIs: Sumita Bhaduri-McIntosh, M.D., Ph.D; and Michael McIntosh, Ph.D.

Overlap with current application: None

Sponsor: NATL INST OF HLTH NCI
NIH NCI 1U01 CA275310

6/1/2023 – 5/31/2025

FL 2023 NBAF Fellowship Program

PI: Michael McIntosh, Ph.D.
Sponsor: US DEPT OF AG APHIS
USDA APHIS CRM 6000027242

6/1/2023 – 5/31/2025

NBAF Fellowship Program in Emerging Diseases

PI: Michael McIntosh, Ph.D.
Sponosr: USDA APHIS CRM 6000027242

Completed Projects

3/23/2022 – 6/30/2024

Biophysical characterization of the EBV Latent Membrane Protein-1 Oncochannel

PI: Michael McIntosh, Ph.D.
Sponsor: Children’s Miracle Network (2909CMCNT)

Jul 2023 – Jun 2024

Lytic Induction Project

PI: Sumita Bhaduri-McIntosh, M.D.
Sponsor: VIRACTA THERAPEUTICS

7/1/21 – 6/1/23

Authentic Human Antiviral Antibody Discovery and Cloning.

PI: Michael McIntosh, Ph.D.
Sponsor: Children’s Miracle Network (2909CMCNT)

Mar 2022 – Aug 2022

Studying the capacity of the EBV protein kinase (BGLF4) plus ganciclovir vs acyclovir to induce cell killing in non-EBV infected A549 cells.

PI: Sumita Bhaduri-McIntosh, M.D.
Sponsor: VIRACTA THERAPEUTICS

9/30/19 – 9/29/22

Recombinant Adeno-associated virus as a long-acting passive antibody vaccine against foreign animal diseases.

PI: Michael McIntosh, Ph.D.
Sponsor: DHS S&T | RSFR-19-00104

Dec 2021 – Dec 2021

Studying the capacity of the EBV protein kinase (BGLF4) plus ganciclovir to induce cell killing in non-EBV infected 293 cells.

PI: Sumita Bhaduri-McIntosh, M.D.
Sponsor: VIRACTA THERAPEUTICS

9/1/20 – 12/31/20

Validation of a COVID-19 Point-of-Care Virus Test.

PI: Michael McIntosh, Ph.D.
Sponsor: Children’s Miracle Network (2909CMCNT)

Nov 2021 – Sep 2022

Nanotinostat and ganciclovir in an oncolytic strategy against EBV-lymphomas

PI: Sumita Bhaduri-McIntosh, M.D.
Sponsor: VIRACTA THERAPEUTICS